

REMARKS/ARGUMENT

The applicants respond to the Office Action of May 20, 2003, in accordance with 37 C.F.R. § 1.111.

Claims 28 through 60 are pending in the application.

The Examiner applies a restriction requirement under 35 U.S.C. § 121 to a single disclosed species. The applicants provide the following election under traverse.

The applicants maintain that the species are encompassed by the applicants' generic claim 28 and should not require separate searching. Reconsideration of the restriction requirement is requested.

According to the Examiner, applicants must elect a specifically named or completely defined active substance plus a specifically named or completely defined dendrimer. Further, the Examiner has requested that applicants specifically name or completely define additional ingredients.

Applicants provisionally elect the dendrimer G' 4-T, depicted as Formula (X) on page 67 of the application, the active ingredient Fenamidone, i.e., (4-S)-4-methyl-2-methylthio-4-phenyl-1-phenylamino-2-imidazolin-5-one, and the additional ingredient, a liquid carrier, for prosecution. The liquid carrier is within the scope of claims 35, 51, and 54, and claims dependent thereon. Useful liquid carriers are described in the application beginning on page 39, at line 17, and continuing to page 40, line 25.

The applicants' election is made with traverse. The applicants believe that the requirement should be withdrawn.

If the Examiner requires any additional information regarding this election, the applicants request the Examiner to contact their attorney as identified below.

Favorable consideration is respectfully requested.

Respectfully submitted,

16 June 03

Date

Paul Grandinetti

Paul Grandinetti

Reg. No. 30,754

OSTROLENK, FABER, GERB & SOFFEN, LLP

1180 Avenue of the Americas

New York, New York 10036-8403

Telephone (202) 429-4560